US developed a new biochip device for diagnosis and treatment of human malignant diseases
Release date: 2010-04-09
Music therapy device by means of "interactive body, sense of music", through physical interaction between children's music transmission activity, meet in the process of development of the special children's physical, psychological, cognitive and social development needs, under the induction of music will mood to automatic vent, and induce the subconscious of children, make its produce association and imagination, in stimulating feeling at the same time.
Relax Massage Chair,Music Glove Hand Therapy,Real Relax Massage Chair,Music Therapy Device jinan Fangqi Sunshine education consulting CO.,LTD. , https://www.fzrehabmarket.com
Scientists at Rice University in the United States have recently developed a new biochip for diagnosis and treatment. This chip can be used to check whether a patient has various malignant diseases. After testing the chip device in 52 patients, the detection is accurate. The rate reached 93%. This kind of equipment has less damage to the human body than traditional testing equipment, and the cost of diagnosis and treatment and the time required for diagnosis and treatment are much lower.
The nano biochip is a semiconductor device that collects, stains, and analyzes human biomarkers, and then determines whether the patient has a malignant disease. The types of detectable diseases are also very rich, from heart disease. AIDS is different from trauma. This chip device can greatly reduce the cost of hospital treatments around the world.
Among them, oral cancer has 300,000 patients every year in the world, and the number of patients suffering from this disease in the United States is expected to be 35,000 this year. The 5-year survival rate of patients suffering from this disease is only 60%, and if it is early If the patient is detected to be suffering from the disease, the 5-year survival rate can be increased to 90%. The advantage of this chip device is that it does not require a biopsy of the patient, and the diagnosis time is only 15 minutes, which is much shorter than the traditional detection method.
According to the inventor of the device, they will continue to try the device in 500 patients in Houston, San Antonio and the UK, and hope that the device will be approved by the Food and Drug Administration (FDA) within 2-4 years. At the same time, the research team is actively developing another chip product. It is reported that the chip can further determine whether the test subject is suffering from a common disease or a malignant disease.
(Source: Kexun)